The Orbis Paxman Hair Loss Prevention System is a new equipment introduced to Hong Kong in 2017. Although this device has been widely used in the United States, Europe and Australia, acceptability, efficacy and safety data in Chinese have not yet been available. The objective of this prospective study is to collect clinical data in Chinese patients using the Orbis Paxman Hair Loss Prevention System to prevent chemotherapy-induced alopecia. This project seeks to demonstrate that the Orbis Paxman Hair Loss Prevention System is safe and effective in reducing chemotherapy-induced alopecia in woman with breast cancer undergoing neoadjuvant or adjuvant chemotherapy.
Study Type
INTERVENTIONAL
Allocation
NA
Purpose
PREVENTION
Masking
NONE
Enrollment
25
Scalp cooling is a physical method to reduce chemotherapy-induced alopecia
Department of Clinical Oncology, Prince of Wales Hospital
Hong Kong, Hong Kong
The success rate of scalp cooling in preventing chemotherapy-induced alopecia
Time frame: 2 year
The rate of preceived hair preservation during and after completion of chemotherapy
It will be assessed by study tool ALOPECIA ASSESSMENT BY PATIENT AND WIG USE FORM
Time frame: 2 years
The quality of life during and after completion of chemotherapy
It will be assessed by study tool EORTC QLQ-30
Time frame: 2 years
The disease site specific quality of life during and after completion of chemotherapy
It will be assessed by study tool EORTC QLQ - BR23
Time frame: 2 years
The incidence of treatment-emergent adverse events of scalp cooling
It will be assessed by COMFORT SCALE FORM.
Time frame: 2 years
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.